DARWIN EU® Prevalence of rare blood cancers in Europe

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

  Other
• Non-interventional study design, other:
  Population-based

Study drug and medical condition

• Medical condition to be studied:
  Follicular lymphoma

  Diffuse large B-cell lymphoma

  Plasma cell myeloma

  Chronic lymphocytic leukaemia

  Acute myeloid leukaemia

  Acute lymphocytic leukaemia

Population studied

• Short description of the study population:
  The study included all individuals reported in the five European databases, including IPCI, SIDIAP, CPRD, IQVIA LPD Belgium, and IQVIA DA Germany, to determine the prevalence of haematological cancers.
• Age groups:
  • Preterm newborn infants (0 – 27 days)
  • Term newborn infants (0 – 27 days)
  • Infants and toddlers (28 days – 23 months)
  • Children (2 to < 12 years)
  • Adolescents (12 to < 18 years)
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Patients with haematological cancers
• Estimated number of subjects:
  10000000

Study design details

• Study design:
  Population-based cohort
• Main study objective:
  To estimate the prevalence of rare blood cancers (follicular lymphoma, diffuse Large B-Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia)
• Outcomes:
  Follicular lymphoma, diffuse Large B-Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic.
• Data analysis plan:
  5-year partial prevalence will be estimated for each outcome of interest.
• Summary results:
  CONCLUSION ; Across the included databases, ALL and AML were the blood cancers with the lowest prevalence, with a 5 year partial point prevalence at less than 1 per 10,000. DLBCL and FL were slightly more common, with estimated prevalence of less than 2 per 10,000 and less than 3 per 10,000, respectively. Lastly, 5-year partial point prevalence as of 1st January 2020 of CLL and MM was also below 5 per 10,000. Differences in analytic settings, in particular whether using partial or complete prevalence, had a meaningful impact on estimates of prevalence. Prevalence also varied substantially across age groups.